According to a press release on November 6th from the official website of British American Tobacco (BAT), the company will deepen its strategic partnership with Canadian marijuana producer Organigram. BAT will invest approximately £74 million (CAD 124.6 million) between January 2024 and January 2025, increasing its stake from around 19% to 45%.
This investment aims to deepen the strategic relationship between Organigram and BAT. Since BAT's initial investment and the establishment of a Product Development Collaboration (PDC) in March 2021, the relationship between the two companies has been further strengthened. The PDC was formed with the objective of combining the knowledge of both companies and developing the next generation of non-combustible cannabis products.
British American Tobacco, in a statement, expressed its satisfaction with Organigram's performance and continued to be impressed by the company's prudent financial governance. "British American Tobacco still supports the category management abilities demonstrated by the Organigram management team, particularly in addressing challenging market conditions," the company stated. "These factors lead us to believe that new investments can allow Organigram to fully capitalize on market opportunities and bring incremental value to both companies.
The majority of investments will be allocated to Organigram, in order to establish a strategic investment fund. This fund aims to expedite Organigram's growth and support regional, technological, and product expansion in the cannabis industry.
According to the British American Tobacco company, this investment still needs to meet customary conditions, including obtaining necessary approval from Organigram shareholders.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
